Active pharmaceutical ingredients (APIs) manufacturer Noramco has announced the launch of Noramco Group, a North American pharmaceutical supply chain services provider.
It integrates the capabilities of two Noramco subsidiaries: drug product contract development and manufacturing organisation (CDMO) Halo Pharma, and Purisys.
The strategic move aims to address the escalating drug shortages and quality concerns in the US by improving supply chain performance and increasing domestic production.
The current crisis in the US pharmaceutical industry is characterised by unreliable foreign supply, insufficient domestic manufacturing capacity and logistical challenges. It has severely impacted the availability of essential medications.
Noramco Group’s launch is a direct response to these issues, with a focus on enhancing supply chain reliability and boosting domestic production capabilities.
The integration of Noramco, Purisys and Halo Pharma is expected to streamline industry processes, reduce logistics costs and enhance regulatory compliance.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
For companies dealing with new chemical entities, the consolidation offers added intellectual property protection through a reliable domestic source.
The Noramco Group’s combined API and drug product CDMO services in North America may also lead to increased opportunities for the National Institutes of Health and other government grants and contracts.
Noramco is a global supplier of commercial APIs, supporting treatments including pain management and drug abuse treatment.
Purisys focuses on clinical API development and manufacturing services, with a focus on controlled substances and pharmaceutical reference standards.
Halo Pharma offers manufacturing services for various dosage forms, serving both brand and generic pharmaceutical clients from development to commercialisation.
Noramco Group CEO Lee Karras stated: “The Covid-19 pandemic exposed critical vulnerabilities in our drug supply chain. Government responses, while well-intentioned, proved to be somewhat superficial, leaving the threat of future disruptions unaddressed.
“The formation of the Noramco Group is our proactive solution to some of these challenges.
“By leveraging our advanced manufacturing capabilities, stringent quality control and compliance measures, and timely delivery, we aim to mitigate the risks associated with drug shortages and ensure a stable and reliable supply of vital APIs and drug products.”
